Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 8841418 Antibodies that specifically bind to TIM3

Patent 8841418 was granted and assigned to Cellerant Therapeutics on September, 2014 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Current Assignee

Cellerant Therapeutics

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Ying-Ping Jiang0

Holger Karsunky0

Date of Patent

September 23, 2014

0

Patent Application Number

135387780

Date Filed

June 29, 2012

0

Patent Citations Received

US Patent 12129485 Blockade of CD2 surface expression and expression of chimeric antigen receptors for immunotherapy of T-cell malignancies

0

US Patent 11746103 ALK-5 inhibitors and uses thereof

US Patent 11753472 Antibodies directed against T cell immunoglobulin and mucin protein 3 (TIM-3)

US Patent 11827704 Antibody molecules to PD-1 and uses thereof

0

US Patent 11926665 Methods of treating cancer with anti-TIM-3 antibodies

0

US Patent 12077554 CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer

0

US Patent 11708412 Methods for treating hematologic cancers

0

US Patent 11712433 Compositions comprising PKM2 modulators and methods of treatment using the same

0

...

Patent Primary Examiner

0

No article content yet.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 8841418 Antibodies that specifically bind to TIM3

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool